A guide to Reference Safety Information (RSI) in clinical trials. Learn the regulatory framework including ICH E6(R3), EU CTIS, and UK 2026 CT Regulations, common pitfalls, and how to avoid SUSAR reporting errors.
Updated 2026 guide to Structured Product Labeling (SPL) and data integrity. Covers FDA mandates, EMA ePI roadmap, Health Canada XML-PM, FHIR standards, and ALCOA+ compliance for pharmaceutical labeling.
Explore the regulatory process for negotiating an FDA boxed warning on drug labeling, from initial NDA review to post-market Safety Labeling Changes (SLCs), with 2025-2026 case studies including HRT warning removal, Elevidys, Carvykti, and COVID vaccine labeling debates.
Learn to write the Highlights of Prescribing Information (HPI). Updated for 2026 with AI labeling tools, the Prescription Information Modernization Act, and generic drug labeling reforms. Covers FDA requirements, PLR, and best practices.
Learn how the FDA's PLLR replaced old pregnancy categories. Updated 2026 guide on drafting clear pregnancy risk summaries for biologics, with ICH E21, IMPACT trial, and PIANO registry data.
This comprehensive 2025 guide details e-labeling (e-IFU) regulations worldwide. See our country-by-country analysis of QR code acceptance for medical devices &
An evidence-based review of NLP in regulatory labeling (updated April 2026). Learn how AI assists medical writers in drafting Prescribing Information (PI/SmPC), including FDA Elsa, FDA-EMA joint AI principles, and current limitations.
A comprehensive guide to transitioning from XML-based SPL to HL7 FHIR for e-labeling. Updated for 2026 with EMA go-live timeline, Jordan mandate enforcement, FDA PQ/CMC STU2, and latest FHIR adoption data.
Updated 2026 guide to FDA off-label promotion regulations for MSL teams, covering the January 2025 SIUU guidance, September 2025 OPDP enforcement surge, USPI boundaries, and compliance best practices
Learn how pharmaceutical translation errors in SmPCs and patient leaflets lead to drug recalls, regulatory sanctions, and patient safety risks. Updated with 2025-2026 EU pharma legislation reform, EMA ePI roadmap, and AI translation developments.
Explore a structured cascade model for rolling out pharma safety labeling updates to global affiliates, covering FDA 505(o)(4) guidance, EMA variations framework, AI-powered PV tools, and sub-90-day implementation strategies.
Updated April 2026 analysis of Google's Gemini 3/3.1 Pro AI for healthcare, pharma, and biotech. Covers MedGemma 1.5, HIMSS 2026 deployments, Isomorphic Labs trials, and FDA/EU regulatory developments.
Learn the difference between a Company Core Data Sheet (CCDS) and local labels. Explore strategies for managing global labeling deviations, including EMA ePI, IDMP compliance, and AI-powered labeling tools for regulatory compliance
Learn the definitions and key differences between basket, umbrella, and platform trials. This guide explains how master protocols work in precision oncology, including 2025-2026 updates on tissue-agnostic approvals, NCI successor trials (ComboMATCH, MyeloMATCH), and evolving FDA guidance.
Updated for 2026: Compare ISO 14155:2026 for medical device trials vs ICH E6(R3) GCP for pharma. Covers scope, risk management, regulatory compliance, and the l
An in-depth guide to adaptive trial design, updated for 2026. Covers ICH E20 guideline, FDA Bayesian guidance, AI-powered trial optimization, and how prespecified changes based on interim data make clinical trials more efficient and ethical.
Learn what Investigator-Initiated Trials (IITs) are and the regulatory responsibilities clinicians face as a Sponsor-Investigator in academic clinical trials, including ICH E6(R3) GCP updates, EU CTIS requirements, and 2025-2026 regulatory changes.
An educational guide to sample size calculation in clinical trials. Learn the roles of statistical power, effect size, and alpha/beta errors in trial design.
Updated 2026 analysis of cell and gene therapy logistics for clinical trials, covering cryogenic cold chain, chain of identity, decentralized manufacturing, and the latest regulatory developments from FDA, EMA, and ICH
Explore the Bid Defense Meeting (BDM), a critical step for CROs to win clinical trial contracts. Updated for 2026 with ICH E6(R3) guidance, AI-driven bid tools, and current CRO market data. Learn key preparation strategies, sponsor criteria, and best practices.
Explore the rise of CRO consolidation in clinical trials, updated for 2026. Covers major M&A deals (Thermo Fisher/Clario, Fortrea spin-off, Syneos take-private), market trends, AI-driven acquisitions, and the impact on pharma sponsors and trial quality
This guide defines Fair Market Value (FMV) for clinical trial investigator compensation. Learn key regulations like the Anti-Kickback Statute and Stark Law to e
Updated 2026 guide to entry-level clinical trial roles. Covers Clinical Trial Assistant (CTA) and IHCRA positions, responsibilities, salary ranges ($47K-$72K), ICH E6(R3) impact, and career paths.
Learn how MedDRA (v29.0) and WHODrug (688K+ products) standardize coding for adverse events and medications in clinical trials. Covers structure, AI-assisted coding, regulatory requirements, and 2026 updates
© 2026 IntuitionLabs. All rights reserved.
